Reduced-intensity haploidentical HCT in myelofibrosis

Current understanding

A phase II trial is evaluating reduced-intensity conditioning (RIC) haploidentical allo-HCT in primary and secondary myelofibrosis, expanding donor options for MF patients who lack matched donors. An initial cohort using pre-transplant JAK inhibition achieved universal engraftment with no graft failure but substantial GVHD, prompting an extension cohort applying JAK inhibitor before, during, and after transplant to reduce GVHD without compromising engraftment. Sits at the execution layer (donor selection + conditioning) but relevant to the decision layer by widening the eligible population beyond matched-donor recipients.

Evidence log

• 2026-07-20 — Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis: cross-connection with peritransplant-ruxolitinib-gvhd: High GVHD after pre-transplant-only JAK inhibition in RIC haplo HCT is the specific rationale driving the peri-transplant JAK inhibition extension in this donor setting. (novelty: 3)

Open questions

Related